Article
Genome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.
Circulation. Cardiovascular genetics - 1 Dec 2014
Lüneburg Nicole, Lieb Wolfgang, Zeller Tanja, Chen Ming-Huei, Maas Renke, Carter Angela M, Xanthakis Vanessa, Glazer Nicole L, Schwedhelm Edzard, Seshadri Sudha, Ikram Mohammad Arfan, Longstreth William T, Fornage Myriam, König Inke R, Loley Christina, Ojeda Francisco M, Schillert Arne, Wang Thomas J, Sticht Heinrich, Kittel Anja, König Jörg, Benjamin Emelia J, Sullivan Lisa M, Bernges Isabel, Anderssohn Maike, Ziegler Andreas, Gieger Christian, Illig Thomas, Meisinger Christa, Wichmann H-Erich, Wild Philipp S, Schunkert Heribert, Psaty Bruce M, Wiggins Kerri L, Heckbert Susan R, Smith Nicholas, Lackner Karl, Lunetta Kathryn L, Blankenberg Stefan, Erdmann Jeanette, Munzel Thomas, Grant Peter J, Vasan Ramachandran S, Böger Rainer H
Abstract excerpt
BACKGROUND: Dimethylarginines (DMA) interfere with nitric oxide formation by inhibiting nitric oxide synthase (asymmetrical DMA [ADMA]) and l-arginine uptake into the cell (ADMA and symmetrical DMA [SDMA]). In prospective clinical studies, ADMA has been characterized as a cardiovascular risk marker, whereas SDMA is a novel marker for renal function and associated with all-cause mortality after ischemic stroke....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.